Fig. 7
From: PTGES3 proteolysis using the liposomal peptide-PROTAC approach
PTGES3-PROTAC inhibited the malignant phenotype of HCC cells in vitro. (A, B) Representative and quantified results of the EdU incorporation assays. HCC cells were treated with FIP-2 or PTGES3-PROTAC (n = 3). (C, D) The proliferation abilities were analyzed and quantified by colony formation assays. FIP-2 or PTGES3-PROTAC was used to treat HCC cells (n = 3). (E, F) Transwell detection of HCC cells treated with FIP-2 or PTGES3-PROTAC. Representative photographs of transwell assays were presented (E). Statistical analysis of the transwell assays (F, n = 3). (G, H) Representative images and quantified data of the wound healing assays. FIP-2 or PTGES3-PROTAC treating HCC showed the reduced migration ability (n = 3)